Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A peptide corresponding to 14 amino acids near the amino terminus of human TLR2.|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||10 ug/ml|
|Immunofluorescence (IF)||10 ug/ml|
|Immunohistochemistry (IHC)||2 ug/ml|
|Western Blot (WB)||1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
Despite its predicted molecular weight, TLR2 often migrates at ~100kDa in SDS-PAGE. A suggested positive control is A-20 cell lysate.
PA5-20020 can be used with blocking peptide PEP-0139.
Toll-like receptors (TLRs) are signaling molecules that recognize different microbial products during infection and serve as an important link between the innate and adaptive immune responses. These proteins act through adaptor molecules such as MyD88 and TIRAP to activate various kinases and transcription factors such as Protein Kinase C (PKC) alpha/beta and NF-kappa-B. TLR2 can form heterodimers with either TLR1 or TLR6, and as a heterodimer can recognize a variety of bacterial and mycoplasma lipoproteins respectively.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice.
PA5-20020 was used in immunohistochemistry - paraffin section to determine if beta-Adrenergic signaling contributes to initiation and progression of breast cancer
|Abdin AA,Soliman NA,Saied EM||Pharmacological reports : PR (66:1114)||2014|
TIL4; Toll-like Receptor 2; toll/interleukin 1 receptor-like 4; toll/interleukin-1 receptor-like protein 4
CD282; Ly105; TIL4; TLR2